Alan George Clark
Directeur Technique/Scientifique/R&D chez TCB Newco Ltd.
Profil
Alan George Clark is currently a Director at Glykogen Ltd.
and a Director & Chief Technical Officer at TCB Newco Ltd.
He previously worked as a Non-Executive Director at Luperacus Ltd.
from 2016 to 2021, a Director at ILC Therapeutics Ltd.
from 2016 to 2019, and a Director at BioCaptiva Ltd.
from 2018 to 2020.
Dr. Clark holds a doctorate degree from The University of Edinburgh and an undergraduate degree from Heriot-Watt University.
Postes actifs de Alan George Clark
| Sociétés | Poste | Début |
|---|---|---|
Glykogen Ltd.
 Glykogen Ltd. Pharmaceuticals: MajorHealth Technology Glykogen Ltd. engages in the development of anti-glycan monoclonal antibodies using a novel and innovative process. The company was founded on October 11, 2016 and is headquartered in Fife, the United Kingdom. | Directeur/Membre du Conseil | 13/02/2017 |
TCB Newco Ltd.
 TCB Newco Ltd. Pharmaceuticals: MajorHealth Technology TCB Newco Ltd. provides clinical services. It develops CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. The company was founded on July 5, 2021 and is headquartered in Motherwell, GB. | Directeur Technique/Scientifique/R&D | - |
Anciens postes connus de Alan George Clark
| Sociétés | Poste | Fin |
|---|---|---|
Luperacus Ltd.
 Luperacus Ltd. BiotechnologyHealth Technology Luperacus Ltd. develops novel therapeutic antibodies to treat canine and human cancer. The company was founded by Alan G. Clark and is headquartered in Glasgow, the United Kingdom. | Directeur/Membre du Conseil | 29/10/2021 |
BioCaptiva Ltd.
 BioCaptiva Ltd. BiotechnologyHealth Technology BioCaptiva Ltd. is a British medical device company that is developing the BioCaptis, a device that can transform liquid biopsy testing for cancer management. The company is based in Edinburgh, UK. The BioCaptis captures up to 100x more cell-free DNA (cfDNA) than a venous blood draw, yielding high-quality and quantity cfDNA for testing, which addresses the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. BioCaptiva was founded in 2021 when it spun out from the University of Edinburgh. The CEO is Jeremy Wheeler. | Directeur/Membre du Conseil | 01/06/2020 |
ILC Therapeutics Ltd.
 ILC Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services ILC Therapeutics Ltd. is a British biotechnology company that conducts research and experimental development. The company is based in Lanarkshire, UK. The company was founded by William H. Stimson. Alan Keith Walker has been the CEO of the company since 2020. | Directeur/Membre du Conseil | 01/05/2019 |
Formation de Alan George Clark
| The University of Edinburgh | Doctorate Degree |
| Heriot-Watt University | Undergraduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 5 |
|---|---|
Luperacus Ltd.
Luperacus Ltd. BiotechnologyHealth Technology Luperacus Ltd. develops novel therapeutic antibodies to treat canine and human cancer. The company was founded by Alan G. Clark and is headquartered in Glasgow, the United Kingdom. | Health Technology |
Glykogen Ltd.
Glykogen Ltd. Pharmaceuticals: MajorHealth Technology Glykogen Ltd. engages in the development of anti-glycan monoclonal antibodies using a novel and innovative process. The company was founded on October 11, 2016 and is headquartered in Fife, the United Kingdom. | Health Technology |
ILC Therapeutics Ltd.
ILC Therapeutics Ltd. Miscellaneous Commercial ServicesCommercial Services ILC Therapeutics Ltd. is a British biotechnology company that conducts research and experimental development. The company is based in Lanarkshire, UK. The company was founded by William H. Stimson. Alan Keith Walker has been the CEO of the company since 2020. | Commercial Services |
BioCaptiva Ltd.
BioCaptiva Ltd. BiotechnologyHealth Technology BioCaptiva Ltd. is a British medical device company that is developing the BioCaptis, a device that can transform liquid biopsy testing for cancer management. The company is based in Edinburgh, UK. The BioCaptis captures up to 100x more cell-free DNA (cfDNA) than a venous blood draw, yielding high-quality and quantity cfDNA for testing, which addresses the major challenge of liquid biopsy in cancer management. This will potentially allow the testing of a far greater number of cancer types and stages in a much wider range of patients. BioCaptiva was founded in 2021 when it spun out from the University of Edinburgh. The CEO is Jeremy Wheeler. | Health Technology |
TCB Newco Ltd.
TCB Newco Ltd. Pharmaceuticals: MajorHealth Technology TCB Newco Ltd. provides clinical services. It develops CAR-T cell therapy products for the treatment of cancer, as well as developing gamma delta T cell therapies for the treatment of infectious disease. The company was founded on July 5, 2021 and is headquartered in Motherwell, GB. | Health Technology |
